briciclib sodium

Drug Overview

Briciclib sodium is a highly advanced, experimental cancer medicine currently being studied in clinical trials. It belongs to a modern family of cancer treatments known as Targeted Therapies or “Smart Drugs.” Unlike standard chemotherapy that attacks all fast-growing cells in the body, briciclib sodium is designed to find and block a very specific protein that cancer cells need to survive and multiply.

Because it is still in the research and testing phases, briciclib sodium is not yet available at standard pharmacies. It is only given to patients who volunteer to participate in strictly monitored clinical research studies.

• Generic Name: Briciclib sodium (also known in research as ON 013105)
• US Brand Names: None (Currently an Investigational Agent)
• Drug Class: eIF4E Inhibitor / Translation Initiation Inhibitor
• Route of Administration: Intravenous (IV) Infusion (delivered directly into a vein)
• FDA Approval Status: Not FDA Approved. It is strictly an investigational drug used in medical research.

What Is It and How Does It Work? (Mechanism of Action)

Briciclib sodium is a Targeted Therapy designed to shut down the “protein factories” inside cancer cells. To understand how it works, we have to look at how cells build the tools they need to grow.

In human cells, DNA sends instructions to build proteins. The process of reading these instructions and building the protein is called “translation.” For this process to start, the cell uses a microscopic “starter switch” called eIF4E (eukaryotic translation initiation factor 4E). In many aggressive cancers, the eIF4E switch is stuck in the “ON” position, causing the cell to rapidly overproduce proteins that make the cancer grow, spread, and hide from the immune system. Two of the most dangerous proteins it builds are called c-Myc and Cyclin D1.

At the molecular level, briciclib sodium works by binding directly to the eIF4E protein. By locking onto this starter switch, the drug physically blocks the translation process. Because the switch is jammed, the cancer cell can no longer build c-Myc, Cyclin D1, or other survival proteins. Without these vital proteins, the cancer cell can no longer multiply and is quickly forced into a state of programmed cell death (a natural destruction process called apoptosis).

FDA Approved Clinical Indications

Because briciclib sodium is still an investigational medicine undergoing early clinical trials, it does not currently have any official FDA-approved uses for the general public.

Oncological Uses (Investigational)

• Studied for the treatment of relapsed or refractory Lymphoma (such as Mantle Cell Lymphoma).
• Studied for the treatment of Philadelphia chromosome-negative B-cell Acute Lymphoblastic Leukemia (B-cell ALL).
• Studied for the treatment of advanced solid tumors that have not responded to standard therapies.

Non-Oncological Uses

• There are no FDA-approved or investigational non-oncological uses for this drug at this time. It is being developed strictly for cancer.

Dosage and Administration Protocols

Because briciclib sodium is an investigational drug, there is no single, commercially available dosage. The exact amount a patient receives is carefully determined by the specific rules (protocol) of the clinical trial they are enrolled in.

• 
  Renal and Hepatic Insufficiency: Because this is an experimental drug, precise dose adjustments for patients with kidney (renal) or liver (hepatic) disease are not yet fully established. Typically, patients with severe liver or kidney problems are excluded from Phase 1 trials to ensure their safety. During the trial, if blood tests show stress on these organs, the research doctor will immediately lower the dose or pause the medication.

Clinical Efficacy and Research Results

Current research (spanning 2020-2025) on briciclib sodium is primarily focused on laboratory data and early Phase 1 safety trials. Because it has not reached the final stages of human testing, large-scale numerical data—such as exact 5-year survival rates—are not yet available.

• Effects on Disease Progression: In laboratory studies and animal models (such as mice with human Mantle Cell Lymphoma), briciclib sodium has shown a strong ability to trigger cancer cell death and significantly shrink tumor burden.
• Combination Therapies: Research indicates that briciclib sodium works exceptionally well when paired with other targeted treatments, such as rituximab. In early models, this combination reduced tumor sizes much more effectively than either drug used alone.
• Ongoing Evaluation: Scientists are actively collecting safety data and looking for early signs of tumor shrinkage in human patients to determine exactly how well the drug extends progression-free survival.

Safety Profile and Side Effects

Like all targeted therapies that alter cellular processes, briciclib sodium can cause side effects. Because it is an investigational drug, there is no formal “Black Box Warning” at this time, but trial participants are monitored extremely closely by their medical team.

Common Side Effects (>10%)

(Based on early trials and similar translation-inhibitor drugs)

• Fatigue: Feeling unusually tired, weak, or lacking energy.
• Gastrointestinal Upset: Mild nausea, vomiting, or diarrhea.
• Infusion Site Reactions: Mild redness, swelling, or irritation where the IV needle is placed.

Serious Adverse Events

• Myelosuppression: A drop in healthy blood cell counts, which can lead to an increased risk of infections (low white blood cells) or anemia (low red blood cells).
• Hepatotoxicity: Liver inflammation, which can be detected by elevated liver enzymes on a routine blood test.

Management Strategies

• If blood counts drop too low, the clinical trial doctor will pause the drug until the bone marrow recovers.
• Patients are usually given anti-nausea medications before the IV infusion to keep their stomachs calm and comfortable.

Research Areas

While briciclib sodium is a targeted therapy, its unique mechanism of action makes it a subject of great interest in Stem Cell Research and Regenerative Medicine. Scientists have discovered that “Cancer Stem Cells”—the deeply hidden, stubborn cells responsible for causing cancer to return after chemotherapy—rely heavily on the eIF4E protein to survive. Current research is exploring whether blocking eIF4E with drugs like briciclib sodium can permanently eradicate these cancer stem cells. If successful, this could stop tumors from regenerating, offering a potential pathway to long-term remission when combined with modern Immunotherapies.

Patient Management and Practical Recommendations

Pre-Treatment Tests to be Performed

Before joining a clinical trial for briciclib sodium, patients will undergo comprehensive health checks:

• Complete Blood Count (CBC): To ensure red blood cells, white blood cells, and platelets are at a safe baseline.
• Comprehensive Metabolic Panel (CMP): To deeply evaluate liver and kidney function.
• Tumor Biopsy or Scans: To accurately measure the size of the tumors before starting the trial.

Precautions During Treatment

• Patients will need frequent blood tests (often weekly) to closely monitor how their liver and bone marrow are handling the investigational drug.
• Patients must stay highly hydrated to help their kidneys process the medication safely.

Do’s and Don’ts

• DO report any signs of infection, such as a fever over 100.4°F (38°C), chills, or a cough, to your study doctor immediately.
• DO attend all scheduled clinic visits, as exact timing is critically important in clinical trials.
• DON’T take any new over-the-counter pain medicines, vitamins, or herbal supplements without asking your research team, as they might interfere with the study drug.
• DON’T ignore any pain, burning, or swelling at your IV site during or after the infusion; let your nurse know right away.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Briciclib sodium is an investigational product and is not approved by the FDA for the treatment, cure, or prevention of any disease. Treatment protocols, dosages, and side effects vary by individual and by specific clinical trial guidelines. Patients should always consult with their primary oncologist or a qualified healthcare professional regarding diagnosis, clinical trial options, and the management of medical conditions. Do not disregard professional medical advice or delay in seeking it because of something you have read in this material.